Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spruce Biosciences, Inc.    SPRB

SPRUCE BIOSCIENCES, INC.

(SPRB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/17/2020 11/18/2020 11/19/2020 11/20/2020 11/23/2020 Date
24.45(c) 25.29(c) 26.55(c) 26.56(c) 26.08(c) Last
50 106 88 850 68 503 42 343 60 962 Volume
-2.16% +3.44% +4.98% +0.04% -1.81% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -35,2 M - -
Net cash position 2020 149 M - -
P/E ratio 2020 -4,92x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -63,0 M - -
Net cash position 2021 96,8 M - -
P/E ratio 2021 -10,5x
Yield 2021 -
Capitalization 617 M 617 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 15
Free-Float 97,5%
More Financials
Company
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone... 
More about the company
All news about SPRUCE BIOSCIENCES, INC.
11/18SPRUCE BIOSCIENCES : Management's Discussion and Analysis of Financial Condition..
AQ
11/18SPRUCE BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financ..
AQ
11/18SPRUCE BIOSCIENCES : Reports Third Quarter 2020 Financial Results and Provides C..
BU
11/04SPRUCE BIOSCIENCES : to Participate in the Credit Suisse 29th Annual Virtual Hea..
BU
10/14SPRUCE BIOSCIENCES, INC. : Amendments to Articles of Inc. or Bylaws; Change in F..
AQ
10/14SPRUCE BIOSCIENCES : Announces Closing of Upsized Initial Public Offering and Fu..
BU
More news
News in other languages on SPRUCE BIOSCIENCES, INC.

- No features available -

More news
Chart SPRUCE BIOSCIENCES, INC.
Duration : Period :
Spruce Biosciences, Inc. Technical Analysis Chart | SPRB | US85209E1091 | MarketScreener
Technical analysis trends SPRUCE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 33,75 $
Last Close Price 26,08 $
Spread / Highest target 68,7%
Spread / Average Target 29,4%
Spread / Lowest Target 7,36%
EPS Revisions
Managers
NameTitle
Richard A. King Chief Executive Officer & Director
Michael G. Grey Executive Chairman
David Moriarty Vice President-Development Operations
Samir M. Gharib Chief Financial Officer
Rosh Dias Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SPRUCE BIOSCIENCES, INC.0.00%617
LONZA GROUP AG61.38%46 348
MODERNA, INC.416.51%39 979
CELLTRION, INC.66.30%36 064
IQVIA HOLDINGS INC.10.39%32 701
SEAGEN INC.47.09%30 304